Dr. John Barton has contributed to 3 publications.
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris, H. A.,Infante, J. R.,Anthony Greco, F.,Thompson, D. S.,Barton, J. H.,Bendell, J. C.,Nambu, Y.,Watanabe, N.,Jones, S. F.; Cancer Chemother. Pharmacol.. 1900 Jan 01.
See more >>
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory m...
Bendell, J. C.,Jones, S. F.,Hart, L.,Spigel, D. R.,Lane, C. M.,Earwood, C.,Infante, J. R.,Barton, J.,Burris, H. A.; Invest New Drugs. 2014 Oct 23.
See more >>
22 citations Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology...
Yardley DA, Burris HA, Clark BL, Shipley D, Rubin M, Barton J, Arrowsmith E, Hainsworth JD; Clin. Breast Cancer. 2011-06-01.
See more >>